Why the study?
Does Andexanet Alfa reverse factor Xa inhibitor activity in healthy, older volunteers established on apixaban?
Does Andexanet Alfa reverse factor Xa inhibitor activity in healthy, older volunteers established on apixaban?
Answers are grounded in this paper and cite their sources.
This commentary discusses a Phase 3a trial of Andexanet Alfa as a reversal agent for factor Xa inhibitors.
Commentary on: Siegal DM, Curnette JT, Connolly SJ, et al. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24.[OpenUrl][1][CrossRef][2][PubMed][3] Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal agent for DOACs, idarucizumab recently received Food and Drug Administration approval as the reversal of the direct thrombin inhibitor, dabigatran. A reversal agent for the factor Xa-inhibitors, Andexanet Alfa is the subject of a recent Phase 3a trial and the core topic of this commentary.2 In a two-part, randomised, placebo-controlled study, healthy, older volunteers were established on 5 mg of apixaban twice daily or 20 mg of … [1]: {openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D373%26rft.spage%253D2413%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa1510991%26rft_id%253Dinfo%253Apmid%252F26559317%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1056/NEJMoa1510991&link_type=DOI [3]: /lookup/external-ref?access_num=26559317&link_type=MED&atom=%2Febmed%2F21%2F3%2F96.atom
No takes yet. Share an insight, caveat, or question.
Ghadimi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: